椎基底动脉延长扩张症动脉瘤治疗与影像监测的成本效果分析
研究采用马尔可夫模型比较椎基底动脉延长扩张症动脉瘤立即治疗与不同间隔影像随访的成本效果,数据取自现有文献。基础分析显示早期治疗(开放手术或血管内操作)最具成本效果,成本388,946.24美元、效果11.0质量调整生命年,净货币效益最高,蒙特卡洛模拟成本效果可接受度近97%。 annual缺血风险<3.3%时MRA监测才具成本效果,6个月随访优于1年或2年间隔。
要点
- 基础分析中早期治疗的成本效果最佳,净货币效益最高。
- 仅在年缺血风险<3.3%时,MRA监测才具成本效果。
- 6个月MRA随访的成本效果优于1年或2年间隔。
核心结论
- 早期治疗(开放手术或血管内操作)是椎基底动脉延长扩张症动脉瘤最具成本效果的策略,净货币效益最高。
研究设计与样本
- 构建马尔可夫决策模型,比较立即治疗与6个月、1年、2年间隔定期随访。
- 模型输入数据提取自当前文献。
- 分析成本、效果、增量成本效果比和净货币效益,并行确定性敏感性分析与蒙特卡洛模拟概率敏感性分析。
主要发现
- 基础分析中早期治疗成本388,946.24美元、效果11.0质量调整生命年,净货币效益最高。
- 确定性敏感性分析结论稳健,蒙特卡洛模拟成本效果可接受度近97%。
- 当年卒中、脑出血、增长和破裂风险均很低时,可考虑每6个月或每年随访。
关键数值与推荐
- MRA监测的成本效果仅见于年缺血风险<3.3%的场景。
- 6个月随访MRA比1年或2年间隔更具成本效果。
- 风险增加时预防性治疗始终提供更高净货币效益。
临床怎么用
- 对椎基底动脉延长扩张症动脉瘤,在年缺血风险≥3.3%时优先考虑早期预防性治疗。
- 仅在年缺血风险<3.3%时考虑MRA监测,并优先选择6个月间隔。
- 治疗决策需结合患者和动脉瘤特异性因素评估治疗风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vertebrobasilar dolichoectatic aneurysms are a rare type of intracranial aneurysm and are generally associated with a poor prognosis due to high rates of morbidity and mortality secondary to ischemic stroke, mass effect, and intracerebral hemorrhage (ICH) or subarachnoid hemorrhage from rupture. When symptomatic, these lesions often mandate treatment. The aim of this study was to explore the most cost-effective management strategy for dolichoectatic aneurysms. METHODS: A decision algorithm was built with a Markov model to compare immediate treatment versus regular follow-up at different intervals (6-month and 1- and 2-year intervals) for dolichoectatic aneurysms. Input data for the model were extracted from the current literature. Costs, effects, incremental cost-effectiveness ratios, and net monetary benefits (NMBs) were analyzed. Deterministic sensitivity analysis and probabilistic sensitivity analysis with Monte Carlo simulation were performed to evaluate the robustness of the model. RESULTS: On base case analysis, early treatment for dolichoectatic aneurysms, either through open surgery or endovascular procedure, is the most cost-effective strategy (cost $388,946.24, effectiveness 11.0 quality-adjusted life years), showing the highest NMB. The conclusion remains robust in deterministic sensitivity analysis as well as in Monte Carlo simulation with near 97% cost-effectiveness acceptability. When annual risks of stroke, ICH, growth, and rupture are all very low, a strategy of follow-up every 6 months or annually can be considered. CONCLUSIONS: The cost-effectiveness of MR angiography (MRA) surveillance is only observed in scenarios with an annual ischemic risk < 3.3%, with 6-month follow-up MRA being more cost-effective than that at 1- or 2-year intervals. In contrast, preventive treatment consistently offers a higher NMB when risk increases. The risk of treatment based on patient and aneurysm specific factors should also be considered in the decision to treat.
引用
- Salih M, Mensah E, Ramirez-Velandia F, et al. Cost-effectiveness analysis on treatment versus imaging surveillance for vertebrobasilar dolichoectatic aneurysms. J Neurosurg. 2026. PMID: 41616313. doi:10.3171/2025.9.JNS251310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。